Key facts
- This page summarizes Julianne Bruno's Form 4 filing for CRISPR Therapeutics AG (CRSP).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Mar 2025, 17:35.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Footnote F2
Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
Footnote F3
This restricted stock unit award was granted on March 20, 2024 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.